Kinnate to Sell Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Lab

 

• Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

• The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.

• This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts in the field of precision oncology and provide it the opportunity to broaden its reach to patients in need for targeted therapies in RAF and RAS solid tumors.  

https://finance.yahoo.com/news/kinnate-biopharma-inc-sells-investigational-133500289.html